A new aim for targeted biopsies in Barrett’s esophagus

Patients with Barrett's esophagus (BE) are at an increased risk for the development of esophageal adenocarcinoma. This risk is relatively low in patients with nondysplastic BE (∼0.1%-0.3% per year) but much higher in patients with BE and high-grade dysplasia (∼6% per year). Several gastroenterology societies recommend interval surveillance for patients with nondysplastic BE, whereas endoscopic eradication therapy is reserved for patients with BE and associated dysplasia or early neoplasia.1-3 The accurate detection of dysplasia associated with BE is therefore instrumental to the management of this disease.

http://ift.tt/2vFgdjH